Treatment therapies for adults with RSV have been elusive, but there are promising breakthroughs on the horizon. Join Drs Forest Arnold and Richard Plemper as they discuss.
Correct. And, of course, the issue with all of the antibody treatments is that they don't induce or generate immune memory. It's not a vaccine, right? Meaning that when the antibody titer ultimately goes down after a few months after administration, then the child is immunologically naive to RSV.
A number of those entry inhibitors have been explored and several were actually advanced to clinical trials and quite advanced stages of clinical testing. The trailblazer was presatovir, a small molecule entry inhibitor originally developed by Gilead. It has really set the roadmap for clinical testing and clinical evaluation of RSV drugs in general. Presatovir initially performed very well.
Older adults, due to immunosenescence — aging of the immune system, different quality of the immune response — become more vulnerable to severe RSV. In adults aged 65 and older in the US, we see 200,000 hospitalizations due to severe RSV per year and about 20,000 deaths per year. I think it's an important point to make and emphasize that you said that the small molecules will bind and prevent the pre-F protein from going to post-fusion protein, and the RSV wants it to go to the post-fusion protein, right? What's the benefit there?. That's very unusual because energetically, it folds when it's synthesized, not into an energy, which would be a thermodynamic minimum. It actually folds into a very high-energetic state.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
FDA approves antibody to protect infants from RSV | CNNParents and pediatricians will have a new option this fall to protect babies from a lung-attacking virus that is the leading cause of hospitalization in infants under a year of age in the United States every year.
Baca lebih lajut »
FDA approves new drug to protect babies from RSVThe FDA approved a new drug to protect babies from RSV, the leading cause of hospitalization for U.S. infants.
Baca lebih lajut »
New drug to protect babies and toddlers from RSV gets FDA approval ahead of cold seasonLast year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
Baca lebih lajut »
FDA approves antibody shot to protect infants from potentially deadly virus RSVThis injection was approved to protect against the annual leading cause of hospitalization in infants under a year old in the U.S.
Baca lebih lajut »
FDA approves antibody shot to protect infants from potentially deadly virus RSVThis injection was approved to protect against the annual leading cause of hospitalization in infants under a year old in the U.S.
Baca lebih lajut »
New drug to protect babies and toddlers from RSV gets FDA approval ahead of cold seasonLast year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
Baca lebih lajut »